ylliX - Online Advertising Network
Company Ticker News

Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types

Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

In a Phase I study across nine tumor types, Agenus Inc’s (NASDAQ: AGEN) CTLA-4 drug AGN1181 posted one complete response and three partial responses (PRs) as a monotherapy, according to data presented t SITC. The three responders expressed the low-affinity FcγRIIIA receptor, Agenus said, which is associated with a lack of response to first-generation CTLA-4 inhibitors.

...read full article on Benzinga

ylliX - Online Advertising Network